ALBANY MOLECULAR RESEARCH, INC. (NASDAQ:AMRI) Files An 8-K Other Events
Item 8.01 Other Events.

Sodium Nitroprusside Injection, one of the Company’s products developed to a drug product co-development agreement with a partner, was launched, following the approval of such product by the FDA on December 8, 2016.

About ALBANY MOLECULAR RESEARCH, INC. (NASDAQ:AMRI)

Albany Molecular Research, Inc. is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM). The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small-scale commercial manufacturing. API includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates and high potency and controlled substance manufacturing. DPM includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized injectable formulations. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

ALBANY MOLECULAR RESEARCH, INC. (NASDAQ:AMRI) Recent Trading Information

ALBANY MOLECULAR RESEARCH, INC. (NASDAQ:AMRI) closed its last trading session up +0.30 at 18.58 with 141,201 shares trading hands.